Brokerages Set Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Target Price at $67.50

Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) have been assigned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $67.50.

A number of equities analysts recently weighed in on ETON shares. Canaccord Genuity Group boosted their target price on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a report on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Friday, July 17th. B. Riley Financial restated a “buy” rating and set a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a research note on Friday, August 14th. Zacks Research raised shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, August 24th. Finally, HC Wainwright raised their target price on shares of Eton Pharmaceuticals from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, August 14th.

Insider Buying and Selling at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, insider David Krempa sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $65.07, for a total value of $1,626,750.00. Following the sale, the insider owned 37,025 shares in the company, valued at $2,409,216.75. This represents a 40.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jennifer Mckie Adams sold 50,000 shares of Eton Pharmaceuticals stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total value of $1,624,000.00. Following the transaction, the director owned 50,000 shares of the company’s stock, valued at $1,624,000. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 125,000 shares of company stock worth $6,204,250 over the last 90 days. Company insiders own 16.49% of the company’s stock.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ETON. HighTower Advisors LLC raised its position in shares of Eton Pharmaceuticals by 187.2% in the second quarter. HighTower Advisors LLC now owns 52,907 shares of the company’s stock valued at $1,915,000 after purchasing an additional 34,484 shares during the period. California State Teachers Retirement System grew its stake in Eton Pharmaceuticals by 838.9% in the 2nd quarter. California State Teachers Retirement System now owns 13,032 shares of the company’s stock valued at $472,000 after buying an additional 11,644 shares during the last quarter. Sigma Planning Corp acquired a new position in Eton Pharmaceuticals in the 2nd quarter valued at about $1,086,000. Toth Financial Advisory Corp bought a new position in Eton Pharmaceuticals in the 2nd quarter valued at about $43,000. Finally, Navellier & Associates Inc. acquired a new stake in Eton Pharmaceuticals during the second quarter worth approximately $652,000. 27.86% of the stock is owned by institutional investors.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ ETON opened at $58.45 on Monday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.52 and a quick ratio of 1.30. The business has a 50-day moving average of $47.78 and a 200-day moving average of $33.45. The stock has a market capitalization of $1.67 billion, a price-to-earnings ratio of 153.82 and a beta of 0.90. Eton Pharmaceuticals has a fifty-two week low of $14.27 and a fifty-two week high of $66.37.

Eton Pharmaceuticals (NASDAQ:ETON) last released its earnings results on Thursday, August 13th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.24. The business had revenue of $37.59 million for the quarter, compared to analyst estimates of $27.11 million. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. As a group, sell-side analysts predict that Eton Pharmaceuticals will post 1.13 earnings per share for the current fiscal year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.